Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Aspergillosis

ClinicalTrials.gov lists 176 trials for Aspergillosis or a narrower condition beneath it.

MeSH D001228 Infections C01 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 8 Phase 1/2 Phase 1/2 2 Phase 2 Phase 2 28 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 22 Phase 4 Phase 4 14 Not applicable Not applicable 12 Observational Observational 78 Phase 1 Phase 1 8 Phase 1/2 Phase 1/2 2 Phase 2 Phase 2 28 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 22 Phase 4 Phase 4 14 Not applicable Not applicable 12 Observational Observational 78

Trials per phase (log scale)

1 more section with rows

95 of the 176 trials are tagged with Aspergillosis itself; the rest are tagged with a narrower condition beneath it.

Get the Aspergillosis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Aspergillosis trials start? (31)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 14

1991: 1 trials (Phase 2 1) 1997: 2 trials (Observational 1, Phase 3 1) 1998: 2 trials (Phase 3 1, Phase 1 1) 1999: 4 trials (Phase 3 3, Phase 2 1) 2000: 2 trials (Phase 2/3 1, Phase 1 1) 2001: 2 trials (Phase 3 1, Phase 2 1) 2002: 2 trials (Phase 2/3 1, Phase 2 1) 2003: 3 trials (Phase 4 2, Phase 2 1) 2004: 2 trials (Observational 1, Phase 2 1) 2005: 2 trials (Observational 1, Phase 2/3 1) 2006: 4 trials (Observational 2, Phase 3 1, Phase 2 1) 2007: 6 trials (Observational 3, Phase 4 1, Phase 3 1, Phase 2 1) 2008: 8 trials (Observational 1, Phase 4 4, Phase 3 3) 2009: 4 trials (Observational 3, Phase 2/3 1) 2010: 9 trials (Observational 6, Not applicable 1, Phase 4 1, Phase 2 1) 2011: 6 trials (Observational 1, Phase 2/3 1, Phase 2 4) 2012: 4 trials (Observational 1, Phase 4 1, Phase 3 1, Phase 1/2 1) 2013: 5 trials (Observational 2, Phase 3 1, Phase 2/3 2) 2014: 10 trials (Observational 2, Phase 4 3, Phase 3 1, Phase 2/3 1, Phase 2 3) 2015: 5 trials (Observational 3, Not applicable 1, Phase 1 1) 2016: 4 trials (Observational 2, Phase 3 1, Phase 2/3 1) 2017: 10 trials (Observational 3, Not applicable 3, Phase 4 1, Phase 3 1, Phase 1/2 1, Phase 1 1) 2018: 6 trials (Observational 4, Phase 3 1, Phase 2 1) 2019: 14 trials (Observational 5, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 4, Phase 1 2) 2020: 9 trials (Observational 4, Phase 2/3 1, Phase 2 2, Phase 1 2) 2021: 13 trials (Observational 9, Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 1) 2022: 8 trials (Observational 4, Not applicable 3, Phase 3 1) 2023: 7 trials (Observational 5, Phase 3 1, Phase 2 1) 2024: 5 trials (Observational 4, Phase 2 1) 2025: 11 trials (Observational 10, Phase 2 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 4
2025 11
2024 5
2023 7
2022 8
2021 13
2020 9
2019 14
2018 6
2017 10

Showing 10 of 31 earlier years.

Start your 14-day trial Email me all 31 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 4 trials starting in 2026 and about 7 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 4 already registered with a 2026 start date: at the cutoff, 2 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.

Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 107 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Aspergillosis trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 8
Phase 1/2 2
Phase 2 28
Phase 2/3 11
Phase 3 22
Phase 4 14
Not applicable 12
Observational 78
Expanded access 1

How many Aspergillosis trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 5
Recruiting 18
Active, not recruiting 4
Completed 103
Suspended 1

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Aspergillosis trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Merck Sharp & Dohme LLC 10
Pfizer 10
National Cancer Institute (NCI) 6
Astellas Pharma Inc 5
Pulmocide Ltd 5

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Aspergillosis? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Itraconazole 12
AMPHOTERICIN B 6
PC945 4
Anidulafungin 3
PREDNISOLONE 3

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Voriconazole 1% 25
MK0991, caspofungin acetate 9
Comparator: Micafungin sodium 9
Posaconazole PFS 6
Isavuconazole 5

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Aspergillosis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Acute respiratory failure 305 10
Pneumonia 264 16
Sepsis 143 12
Septic shock 122 9
Respiratory failure 110 11

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Aspergillosis? (211)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2025 Yes
Propranolol is efficacious against <i>Aspergillus</i> and <i>Fusarium</i> corneal isolates <i>in vitro</i> and in a murine model of <i>Aspergillus</i> keratitis. Antimicrobial agents and chemotherapy 2025 Yes
Influenza-associated invasive aspergillosis in patients admitted to the intensive care unit in Sweden: a prospective multicentre cohort study. Infectious diseases (London, England) 2024 Yes
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies. Scientific reports 2023 Yes
Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2023 Yes

Showing 5 of 211 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (3)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Aspergillosis Point prevalence Unknown Worldwide Not stated Exact
Aspergillosis Point prevalence Unknown Worldwide Not stated Unspecified
Aspergillosis Point prevalence Unknown Worldwide Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Aspergillosis 1163 Exact Orphanet Rare Disease Ontology (ORDO)
Aspergillosis 1163 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages